Login to Your Account

Pharma: Clinic Roundup

Friday, March 30, 2012
• Eli Lilly and Co. Inc., of Indianapolis, published new Phase II data in The New England Journal of Medicine showing that ixekizumab (LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint of achieving at least a 75 percent improvement in psoriasis area and severity index (PASI) scores from baseline. The study enrolled 142 subjects, and significantly more patients achieved a PASI response in the 150-mg, 75-mg and 25-mg group (82 percent, 83 percent and 77 percent) than the placebo group (8 percent). The 10-mg dose group did not separate from placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription